Crescita Therapeutics (TSX:CTX) COGS-to-Revenue : 0.52 (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Crescita Therapeutics COGS-to-Revenue?

Crescita Therapeutics's Cost of Goods Sold for the three months ended in Mar. 2024 was C$2.59 Mil. Its Revenue for the three months ended in Mar. 2024 was C$5.00 Mil.

Crescita Therapeutics's COGS to Revenue for the three months ended in Mar. 2024 was 0.52.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Crescita Therapeutics's Gross Margin % for the three months ended in Mar. 2024 was 48.26%.

Crescita Therapeutics COGS-to-Revenue Historical Data

The historical data trend for Crescita Therapeutics's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Crescita Therapeutics COGS-to-Revenue Chart

Crescita Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.26

0.28

0.40

0.44

0.41

Crescita Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial															0.41	0.41	0.51	0.35	0.52

Crescita Therapeutics COGS-to-Revenue Calculation

Crescita Therapeutics's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	7.158	/	17.522
	=	0.41

Crescita Therapeutics's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	2.585	/	4.996
	=	0.52

Crescita Therapeutics (TSX:CTX) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Crescita Therapeutics's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	2.585 / 4.996
	=	48.26 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Crescita Therapeutics COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Crescita Therapeutics's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Crescita Therapeutics (TSX:CTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Crescita Therapeutics Inc (TSX:CTX) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

CRRTF:USA

Address

2805, Place Louis-R-Renaud, Laval, QC, CAN, H7V 0A3

Website

https://www.crescitatherapeutics.com

Crescita Therapeutics Inc is a Canadian commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The company has three reportable segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The firm generates its revenue in the form of product sales and out-licensing revenue.

Executives

Knight Therapeutics Inc.

10% Security Holder

Crescita Therapeutics (TSX:CTX) Headlines

No Headlines